Ndr Auto Components Limited
Investor Presentation
Ndr Auto Components Limited has informed the Exchange about Investor Presentation on the Financial Results for the quarter and six months ended 30th September 2026.
BSE & NSE corporate filings with AI summaries
Ndr Auto Components Limited
Ndr Auto Components Limited has informed the Exchange about Investor Presentation on the Financial Results for the quarter and six months ended 30th September 2026.
Nova Agritech Ltd
Nova Agritech Ltd has scheduled a Board Meeting on 14/11/2026 to consider un-audited financial results for the quarter ended 30/09/2026.
Marksans Pharma Ltd
Marksans Pharma Ltd reported Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore. H1FY27 revenue grew 32.9% to ₹1,781 crore, and PAT nearly doubled to ₹303 crore.
Exide Industries Ltd
Exide Industries Ltd has released its Q2 FY 2026-27 investor presentation, highlighting its core business, new energy business, and strategic enablers. The company has a strong presence in the lead-acid and lithium-ion battery markets, with a focus on innovation and sustainability.
Jyothy Labs Ltd
Jyothy Labs Ltd has announced its unaudited financial results for the quarter and half-year ended September 30, 2026, and approved a buyback of up to 68,37,210 equity shares at ₹215 per share, representing 1.86% of the total paid-up equity share capital.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a 2nd interim dividend of INR 5 per equity share. The company has also appointed Ms. Vasuta Agarwal as an Additional Director and approved further investments in its subsidiary company.
NDR Auto Components Ltd
NDR Auto Components Ltd has announced its Q2 and H1FY27 financial results, showing strong growth across key financial metrics. The company's total income, EBITDA, and PAT have increased by 11.2%, 11.1%, and 7.4% respectively on a year-over-year basis. The company has also expanded its order book and capacity, and has entered into a joint venture with DYA, a leading seat supplier to Hyundai & Kia in Korea.
Marksans Pharma Limited
Marksans Pharma Limited has reported its unaudited financial results for the quarter and half year ended September 30, 2026, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.
Autoriders International Ltd
Autoriders International Ltd has scheduled a board meeting on November 13, 2026, to consider and approve the unaudited financial results for the quarter and six months ended September 30, 2026.
Dhoot Transmission Limited
Dhoot Transmission Limited has informed the Exchange about Investor Presentation for Q2 FY 2026-27 financial results, with a revised presentation due to a typographical error.
Rajshree Polypack Limited
Rajshree Polypack Limited has announced its Q2 and H1 FY2027 financial results, with revenue from operations at ₹102.90 Crores and ₹205.81 Crores respectively, and operating EBITDA at ₹13.05 Crores and ₹27.47 Crores respectively. The company has maintained its operating margins despite a sharp rise in raw material prices and softer export demand. The results also highlight the resilience of the business, with a strong domestic revenue growth of 37.37% YoY in Q2 and a growth of 21.82% YoY in H1.
Rolex Rings Ltd
Rolex Rings Ltd has announced its unaudited financial results for the quarter and half year ended on 30th September, 2026, which were approved by the Board of Directors. The company has also enclosed the statements of assets and liabilities, cash flow statement, and auditor's limited review report.
Marksans Pharma Ltd
Marksans Pharma Ltd has announced its Q2FY27 financial results, with revenue reaching ₹940 crore, up 30.5% YoY, and EBITDA growing 48.3% to a record ₹214 crore.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates, including the outcome of the Board Meeting held on November 04, 2026. The Board considered, noted and approved the un-audited financial results for the quarter and half year ended September 30, 2026, declaration of 2nd Interim Dividend of INR 5/- per equity share, appointment of Ms. Vasuta Agarwal as an Additional Director, and further investment in Subsidiary Company Dr. Lal PathLabs FZCO.
SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd has announced its financial results for the quarter and half-year ended 30th September, 2026, along with the resignation of its Company Secretary & Compliance Officer, Mr. Thirumalesh Tumma, and the appointment of Mr. Manohar Mollama as the new Company Secretary & Compliance Officer.
Meghmani Organics Limited
Meghmani Organics Limited has submitted its unaudited financial results for the second quarter and half year ended September 30, 2026, with a standalone profit of ₹5,812.84 and a comprehensive income of ₹4,555.76.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about General Updates, including the outcome of the Board Meeting, financial results, and disclosure under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015. The company has approved the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th September, 2026. The Board has also considered and approved the resignation of the Company Secretary & Compliance Officer, Mr. Thirumalesh Tumma, and appointed a new Company Secretary & Compliance Officer, Mr. Manohar Mollama.
SGL Resources Ltd
SGL Resources Ltd has announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also approved the appointment of Ms. Nehal Shah as Company Secretary and Compliance Officer, and noted the resignation of Ms. Rehana Vishal Jhankar as Company Secretary and Compliance Officer.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, and declared a 2nd interim dividend of INR 5 per equity share. The company also approved the appointment of Ms. Vasuta Agarwal as an Additional Director and further investment in its subsidiary company.
CSB Bank Limited
CSB Bank Limited has informed the Exchange about the submission of a newspaper publication regarding the notice of postal ballot and remote e-voting for seeking approval of members on certain items of business.